Phlebodia 600 tablets p/o 600mg №18×1

Name:
Phlebodia 600 tab.p/o 600mg №18 Storage conditionsStore at a temperature not exceeding 30°C. Keep out of the reach of children. Expiration date from the date of manufacture3 years
Description:
of goodsPills, film-coated pink, round, biconvex. Pharmacological action The drug has a phlebotonizing effect (reduces vein extensibility, increases vein tone (dose-dependent effect), reduces venous congestion), improves lymphatic drainage (increases the tone and frequency of contraction of lymphatic capillaries, increases their functional density, reduces lymphatic pressure), improves microcirculation (increases resistance capillaries (dose-dependent effect), reduces their permeability), reduces the adhesion of leukocytes to the venous wall and their migration to paravenous tissues, improves oxygen diffusion and perfusion in the skin tissue, and has an anti-inflammatory effect. Enhances the vasoconstrictive action of adrenaline, norepinephrine, blocks the production of free radicals, the synthesis of prostaglandins and thromboxane. Pharmacokinetics Rapidly absorbed from the gastrointestinal tract, found in plasma 2 hours after ingestion. Cmax in blood plasma is reached 5 hours after administration. It is evenly distributed and accumulated in all layers of the wall of the vena cava and saphenous veins of the lower extremities, to a lesser extent – in the kidneys, liver and lungs and other tissues. The selective accumulation of diosmin and / or its metabolites in the venous vessels reaches a maximum by 9 hours after ingestion and persists for 96 hours. Excreted by the kidneys – 79%, intestines – 11%, with bile – 2.4%. Indications for use As part of complex therapy: to eliminate the symptoms of lymphovenous insufficiency of the lower extremities: a feeling of heaviness or fatigue in the legs, pain; additional treatment for microcirculation disorders; symptomatic therapy of acute hemorrhoids. Use during pregnancy and lactation So far, there have been no reports in clinical practice about any side effects when using the drug in pregnant women. Application during pregnancy in the II and III trimesters is possible only on prescription in cases where the expected benefit to the mother outweighs the potential risk to the fetus. In experimental studies, no teratogenic effects on the fetus have been identified. During breastfeeding, the drug is not recommended, because. there is no data on the penetration of the drug into breast milk. Special instructions: Treatment of an acute attack of hemorrhoids is carried out in combination with other drugs, in the absence of a rapid clinical effect, it is necessary to conduct an additional examination and adjust the therapy. Influence on the ability to drive vehicles and control mechanisms There is no evidence of a negative effect of the drug on the ability to drive vehicles and other mechanisms. Contraindications Hypersensitivity to the components of the drug; breastfeeding period; children under 18 years of age; pregnancy (I trimester) (experience is limited). Dosage and administration Before using the drug, you should consult your doctor. The drug is intended for oral administration. With varicose veins of the lower extremities and chronic lymphovenous insufficiency (edema, pain, convulsions), 1 tab. / day is prescribed. on an empty stomach in the morning. The duration of therapy is usually 2 months. With exacerbation of hemorrhoids, the drug is prescribed 2-3 tablets / day. during meals for 7 days. If one or more doses of the drug are missed, it is necessary to continue using the drug as usual and at the usual dose. Overdose Symptoms of overdose are not described. Side effects In rare cases, hypersensitivity to the components of the drug, requiring a break in treatment: on the part of the gastrointestinal tract – dyspeptic disorders (heartburn, nausea, abdominal pain), on the part of the central nervous system – headache. If any of the side effects listed in the instructions get worse, or if you notice any other side effects not listed in the instructions, tell your doctor. Composition Active substance: diosmin in terms of dry matter 600 mg Excipients: talc – 10.24 mg, colloidal silicon dioxide – 3.5 mg, stearic acid – 50.05 mg, microcrystalline cellulose – up to 910 mg. The composition of the film shell: Sepifilm® 002 (hypromellose (E 464) – 9.832 mg, microcrystalline cellulose – 7.866 mg, macrogol 8 stearate type 1 – 1.967 mg); Sepispers® AP 5523 pink (propylene glycol – traces, hypromellose (E 464) – 0.458 mg, titanium dioxide (E 171) – 4.026 mg, crimson dye Ponceau 4R (E 124) – 0.401 mg, black iron oxide (E 172) – 0.13 mg, iron oxide red (E 172) – 0.02 mg); Opagloss® 6000 (carnauba wax (E 903) – 0.075 mg, beeswax (E 901) – 0.075 mg, shellac (E 904) – 0.15 mg, ethanol 95 ° – traces). Interaction with other drugs Clinically significant effects of interaction with other drugs are not described. Release formPills, film-coated pink, round, biconvex. 1 tab. Active substance: diosmin in terms of dry matter 600 mg Excipients: talc – 10.24 mg, colloidal silicon dioxide – 3.5 mg, stearic acid – 50.05 mg, microcrystalline cellulose – up to 910 mg. The composition of the film shell: Sepifilm® 002 (hypromellose (E 464) – 9.832 mg, microcrystalline cellulose – 7.866 mg, macrogol 8 stearate type 1 – 1.967 mg); Sepispers® AP 5523 pink (propylene glycol – traces, hypromellose (E 464) – 0.458 mg, titanium dioxide (E 171) – 4.026 mg, crimson dye Ponceau 4R (E 124) – 0.401 mg, black iron oxide (E 172) – 0.13 mg, iron oxide red (E 172) – 0.02 mg); Opagloss® 6000 (carnauba wax (E 903) – 0.075 mg, beeswax (E 901) – 0.075 mg, shellac (E 904) – 0.15 mg, ethanol 95 ° – traces). 15 pcs. – PVC/aluminum blisters (1) – cardboard packs. 15 pcs. – PVC/aluminum blisters (2) – cardboard packs. 15 pcs. – PVC/aluminum blisters (3) – cardboard packs. Buy Phlebodia 600 tablets p/o 600mg №18×1 Price for Phlebodia 600 tablets p/o 600mg №18×1